Kelly Clarkson GLP-1: How a Regular Patient Would Get Access

What Kelly Clarkson Has Actually Said

Kelly Clarkson's weight loss drew public attention beginning in late 2023, when she appeared noticeably slimmer on "The Kelly Clarkson Show." She did not stay silent.

In an interview published by People in early 2024, Clarkson confirmed she takes a weight loss medication, specifying it was "not Ozempic." She credited a combination of the drug and walking in New York City for her physical change. She did not name the specific compound, and no representative has confirmed further details on the public record.

What "Not Ozempic" Could Mean Clinically

Ozempic is the brand name of semaglutide 0.5 to 2 mg, FDA-approved for type 2 diabetes management. When Clarkson said it was "not Ozempic," she may have been distinguishing her drug from the diabetes formulation specifically. Several other compounds fall into the same or related drug classes.

The most likely candidates, based on public availability and clinical profile, are:

• Wegovy (semaglutide 2.4 mg): the same molecule as Ozempic but at a higher dose, FDA-approved specifically for chronic weight management since June 2021 [1]
• Zepbound (tirzepatide 15 mg): a dual GIP/GLP-1 receptor agonist, FDA-approved for weight management since November 2023 [2]
• Mounjaro (tirzepatide 5 to 15 mg): the diabetes-labeled version of the same tirzepatide molecule

Any of these would be accurate to describe as "not Ozempic." This article treats the clinical question as open and does not assert which specific drug Clarkson uses.

Why Clarkson's Disclosure Matters Clinically

Celebrity disclosure of medication use carries real public health consequences. A 2023 analysis in JAMA Network Open found that internet searches for "Ozempic" and "semaglutide" spiked by more than 300% following high-profile celebrity mentions [3]. That attention brings patients into clinics who may genuinely qualify for treatment and would not have presented otherwise. It also brings patients who do not qualify, creating pressure for off-label or inappropriate prescribing.

The clinical framework for who actually qualifies is straightforward and evidence-based. That is the focus of the rest of this article.

The Clinical Evidence Behind GLP-1 Drugs for Weight Loss

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, an incretin hormone released from the gut after eating. They slow gastric emptying, reduce appetite signaling in the hypothalamus, and increase satiety. These are not stimulant-based diet pills. They act on established physiological pathways. [4]

STEP-1: Semaglutide 2.4 mg

STEP-1 enrolled 1,961 adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, and no type 2 diabetes. Participants received subcutaneous semaglutide 2.4 mg once weekly or placebo for 68 weeks alongside lifestyle counseling.

Results: mean body weight reduction of 14.9% in the semaglutide group versus 2.4% in the placebo group (P<0.001). Approximately 86% of semaglutide participants lost at least 5% of body weight [5]. Adverse events were mostly gastrointestinal and dose-dependent.

SURMOUNT-1: Tirzepatide 15 mg

SURMOUNT-1 enrolled 2,539 adults using the same BMI criteria as STEP-1. The 72-week trial compared tirzepatide at three doses (5 mg, 10 mg, 15 mg) against placebo.

The 15 mg arm produced a mean weight loss of 20.9%, with 57% of participants losing at least 20% of body weight [6]. That depth of response approaches outcomes previously seen only with bariatric surgery in some patient subgroups.

SELECT: Cardiovascular Outcomes

The SELECT trial (N=17,604) enrolled adults with established cardiovascular disease, BMI of 27 or higher, and no diabetes. Weekly semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo over a median follow-up of 33 months [7]. This trial was the basis for the FDA expanding Wegovy's label to include cardiovascular risk reduction in March 2024, which in turn opened Medicare Part D coverage for the indication.

Who Qualifies for a GLP-1 Prescription: The Exact Criteria

The FDA approved semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound) under specific criteria. Prescribers follow these as the baseline, though individual clinical judgment applies.

FDA-Approved Indications

For Wegovy (semaglutide 2.4 mg) [1]:

• BMI of 30 or higher (obesity), OR
• BMI of 27 or higher (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia
• To be used alongside a reduced-calorie diet and increased physical activity

For Zepbound (tirzepatide) [2]:

• Same BMI thresholds as Wegovy
• Same adjunct lifestyle requirement

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines add that a "chronic disease care model" approach should be used, meaning these drugs are not short-term interventions but long-term therapies requiring ongoing medical supervision [8].

Contraindications to Know Before Requesting a Prescription

Prescribers will screen for these conditions before initiating therapy:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pancreatitis history (requires careful risk-benefit discussion)
• Pregnancy or planned pregnancy within the treatment window
• Severe gastrointestinal disease (e.g., gastroparesis)

Patients with type 1 diabetes or those currently taking insulin require specialist coordination, not automatic exclusion, but the prescribing conversation is more complex.

How a Regular Patient Gets Access: Step by Step

The path from "I heard about this medication" to "I have a prescription in hand" has become substantially shorter since 2020. Telehealth expansion and FDA approval of non-diabetes weight-management indications both contributed.

Step 1: Determine Whether You Meet the BMI Threshold

Calculate your BMI using current weight and height. The CDC provides a validated calculator at cdc.gov [9]. If your BMI is 30 or higher, you meet the obesity criterion outright. If your BMI is 27 to 29.9, you need documentation of at least one comorbidity (hypertension, prediabetes, type 2 diabetes, obstructive sleep apnea, dyslipidemia, or non-alcoholic fatty liver disease are the most commonly cited).

Step 2: Gather Your Medical Records

Before any prescriber visit, collect:

• A recent blood pressure reading (within 6 months)
• A recent lipid panel and HbA1c (within 12 months if available)
• A list of current medications (several drugs interact with GLP-1 agents, including insulin secretagogues)
• Documentation of any prior weight-loss interventions attempted

This documentation shortens the intake process and supports prior authorization for insurance.

Step 3: Choose a Care Pathway

Primary care physician: The most traditional route. PCPs can prescribe both Wegovy and Zepbound. Wait times vary from same-week to several months depending on practice. The advantage is continuity of care and direct access to lab ordering.

Obesity medicine specialist: Board-certified obesity medicine physicians (credentialed through the American Board of Obesity Medicine) offer the most specialized weight-loss care. Waitlists at academic centers can run 3 to 6 months.

Telehealth prescribers: Platforms that offer synchronous video or asynchronous questionnaire-based visits can connect patients to licensed prescribers, often within 24 to 72 hours. The prescriber must be licensed in the patient's state. They must conduct a valid clinical evaluation. Any platform that dispenses a prescription without a proper evaluation is operating outside federal prescribing standards.

Step 4: The Clinical Evaluation

Whether in-person or via video, the prescriber will:

1. Confirm BMI and comorbidity status
2. Review contraindications
3. Review current medications for interactions
4. Discuss realistic expectations (weight loss is dose-dependent and takes 12 to 20 weeks to plateau)
5. Explain the dose escalation schedule (semaglutide starts at 0.25 mg weekly and escalates over 16 to 20 weeks to the 2.4 mg maintenance dose; tirzepatide starts at 2.5 mg weekly and escalates over 20 weeks to the target maintenance dose)

Step 5: Navigating Insurance and Cost

This is where many patients stall. Commercial insurance coverage varies widely. Medicare Part D covers Wegovy for the cardiovascular indication (established CVD plus BMI of 27 or higher) as of 2024. Medicaid coverage differs by state.

The list price for Wegovy is approximately $1,349 per month. The list price for Zepbound is approximately $1,060 per month. Manufacturer savings programs (Novo Nordisk's WeGoTogether card and Eli Lilly's Zepbound savings card) may reduce out-of-pocket costs to $25 to $225 per month for commercially insured patients who qualify.

For uninsured patients or those whose plans exclude obesity medications, compounded semaglutide has been available through 503A and 503B pharmacies during the FDA shortage period. The FDA shortage status for semaglutide injections changed in early 2025, affecting compounded availability. Patients should verify current shortage status directly at the FDA drug shortage database [10] before relying on compounded options.

Step 6: Starting the Medication and Follow-Up

The first 8 weeks are the highest-risk period for gastrointestinal side effects. Nausea occurs in approximately 44% of semaglutide 2.4 mg patients and 31% of tirzepatide patients [5][6]. Most cases are mild to moderate and resolve as the body adjusts to the dose escalation. Prescribers may slow the escalation schedule for patients with significant nausea rather than discontinuing the drug.

Follow-up visits at 4, 12, and 24 weeks allow for:

• Weight reassessment and dose titration
• Monitoring of blood pressure, pulse rate, and any gastrointestinal symptoms
• Lab re-check if HbA1c or lipids were borderline at baseline
• Assessment of whether the patient is a "non-responder" (defined as less than 5% weight loss at 12 to 16 weeks), which may prompt a switch to the alternative agent

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Pharmacotherapy for obesity should be considered an adjunct to, not a replacement for, behavioral interventions, and should be continued only if the patient achieves at least a 5% reduction in body weight after 12 to 16 weeks of treatment at the therapeutic dose." [11]

Common Misconceptions Patients Bring to the Clinic

"It's a shortcut."

Weight regain after stopping GLP-1 therapy averages 11.6 percentage points within one year of discontinuation, based on the STEP 1 Extension trial [12]. These are chronic medications for a chronic disease, not a one-time course.

"The celebrity dose is the same as mine."

Dose selection is individualized. A patient with severe nausea at 1.7 mg semaglutide may stay at that dose indefinitely. Reaching the maximum labeled dose is not a clinical requirement.

"Compounded is the same as brand-name."

Compounded semaglutide contains the same active peptide but is not FDA-evaluated for sterility, potency, or bioavailability at the manufacturing level. The FDA's April 2024 statement on compounded semaglutide noted that "patients and health care providers should be aware that FDA has not reviewed these products for safety, effectiveness, or quality." [13]

"My BMI is 26, so I just need a diagnosis."

A BMI of 26 with a single listed comorbidity does not meet the FDA-approved threshold. Some off-label prescribing does occur, but it places the prescriber outside labeled indications and may void insurance coverage. The clinical evidence base for benefit at BMI <27 is limited.

What the Clarkson Disclosure Gets Right (and What It Leaves Out)

Clarkson's public acknowledgment that she uses a weight loss medication, combined with her description of it as part of a broader lifestyle change including daily walking, actually mirrors clinical best practice. No randomized trial of GLP-1 drugs has tested medication alone against behavioral intervention plus medication. The STEP-1 protocol required lifestyle counseling for all participants. The drug augments behavioral effort; it does not replace it.

What the celebrity narrative consistently omits is the ongoing nature of therapy, the cost barrier, the need for prescriber supervision, and the experience of side effects that cause approximately 4 to 7% of patients to discontinue treatment in the first 20 weeks [5].

The American Obesity Association's "Obesity Algorithm 2024" describes obesity as "a chronic, relapsing, neurobiological disease," not a lifestyle failure or a cosmetic condition [14]. Framing GLP-1 therapy in that context changes the conversation from "getting the celebrity drug" to "treating a recognized medical condition with an FDA-approved medication."

Telehealth Access: What to Look For and What to Avoid

Telehealth prescribing of GLP-1 agents is legal and clinically appropriate when conducted properly. The Ryan Haight Online Pharmacy Consumer Protection Act and subsequent DEA rules require a valid prescriber-patient relationship, which means a synchronous clinical evaluation or a prescriber review of a comprehensive asynchronous intake, not just a checkbox form.

Red flags in telehealth GLP-1 platforms:

• No licensed prescriber named on the platform
• No requirement to submit BMI-confirming information
• Prescription issued within minutes of a short survey with no clinical review
• No follow-up protocol offered

Green flags:

• State-licensed prescribers visible on the platform
• Intake form requesting medical history, medication list, and BMI documentation
• Required video visit or structured asynchronous clinical review
• Written follow-up protocol at defined intervals
• Transparent pricing for medication and visits